Valuation Gan & Lee Pharmaceuticals.

Equities

End-of-day quote Shanghai S.E. Other stock markets 09/12/2025			5-day change	1st Jan Change
63.42 ^CNY	+0.02%		-0.92%	+43.81%

01:19am	Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug	MT
11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	74,247	39,499	18,429	31,066	26,332	37,748	-	-
Change	-	-46.8%	-53.34%	68.57%	-15.24%	43.36%	-	-
Enterprise Value (EV) ¹	74,247	39,499	18,429	28,627	25,439	36,407	35,735	34,557
Change	-	-46.8%	-53.34%	55.34%	-11.14%	43.11%	-1.85%	-3.3%
P/E ratio	57.2x	27.2x	-41.8x	87.8x	42.4x	34.3x	26.4x	21.4x
PBR	8.31x	3.88x	-	2.91x	2.4x	3.29x	3.01x	2.73x
PEG	-	2.2x	0x	-0x	0.6x	0.4x	0.9x	0.9x
Capitalization / Revenue	22.1x	10.9x	-	11.9x	8.65x	9x	7.28x	6.27x
EV / Revenue	22.1x	10.9x	-	11x	8.35x	8.68x	6.9x	5.74x
EV / EBITDA	-	-	-	53.2x	32x	26x	19.4x	15.3x
EV / EBIT	51.1x	23.2x	-	90.8x	40.3x	30.1x	22.4x	17.7x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	0.2	1	0.18	0.24	0.3
Rate of return	-	-	-	0.38%	2.27%	0.28%	0.38%	0.47%
EPS ²	2.31	2.59	-0.78	0.6	1.04	1.85	2.405	2.967
Distribution rate	-	-	-	33.3%	96.2%	9.73%	9.98%	10.1%
Net sales ¹	3,362	3,612	-	2,608	3,045	4,196	5,182	6,021
EBITDA ¹	-	-	-	537.8	795.7	1,400	1,847	2,252
EBIT ¹	1,453	1,699	-	315.3	631.5	1,208	1,594	1,951
Net income ¹	1,231	1,453	-439.5	340.1	614.7	1,101	1,446	1,783
Net Debt ¹	-	-	-	-2,439	-892.7	-1,341	-2,013	-3,191
Reference price ²	132.22	70.34	32.58	52.65	44.10	63.42	63.42	63.42
Nbr of stocks (in thousands)	561,540	561,540	565,653	590,049	597,089	595,202	-	-
Announcement Date	14/04/21	27/04/22	30/03/23	24/04/24	24/04/25	-	-	-

¹CNY in Million²CNY

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
GAN & LEE PHARMACEUTICALS.	34.28x	8.68x	26x	0.28%	5.34B
REGENERON PHARMACEUTICALS, INC.	17.05x	4.62x	12.1x	0.52%	72.15B
CSL LIMITED	23.34x	4.25x	12.35x	2.52%	59.28B
UCB	41.48x	6.5x	20.94x	0.57%	54.78B
SAMSUNG BIOLOGICS CO.,LTD.	48.34x	12.78x	27.71x	-.--%	51.37B
BIOGEN INC.	16.85x	2.88x	8.81x	-.--%	26.47B
INCYTE CORPORATION	15.6x	3.01x	9.56x	-.--%	18.98B
INNOVENT BIOLOGICS, INC.	79.12x	9.45x	84.85x	-.--%	18.86B
ALTEOGEN INC.	265.2x	94.51x	143.57x	-	16.69B
BRIDGEBIO PHARMA, INC.	-21.58x	31.3x	-31.7x	-.--%	14.31B
Average	51.97x	17.80x	31.42x	0.43%	33.82B
Weighted average by Cap.	41.10x	11.77x	24.45x	0.68%